Akari Therapeutics Files 8-K: Agreements, Equity Sales, and Board Changes
Ticker: AKTX · Form: 8-K · Filed: Aug 29, 2025 · CIK: 1541157
Sentiment: neutral
Topics: material-agreement, equity-sale, corporate-governance
Related Tickers: AKTX
TL;DR
Akari Therapeutics filed an 8-K detailing new deals, stock sales, and board shuffles.
AI Summary
Akari Therapeutics Plc announced on August 28, 2025, an entry into a material definitive agreement. The company also reported on unregistered sales of equity securities and changes in its board and officer composition, including director departures and elections, and the appointment of certain officers. Additionally, financial statements and exhibits were filed.
Why It Matters
This filing indicates significant corporate actions, including new agreements and potential equity dilution, which could impact the company's financial structure and leadership.
Risk Assessment
Risk Level: medium — The filing mentions unregistered sales of equity securities, which can sometimes signal dilution or financing activities that carry inherent risks.
Key Players & Entities
- Akari Therapeutics Plc (company) — Filer
- Celsus Therapeutics Plc. (company) — Former company name
- Morria Biopharmaceuticals PLC (company) — Former company name
FAQ
What is the nature of the material definitive agreement entered into by Akari Therapeutics?
The filing states an entry into a material definitive agreement but does not provide specific details about its nature in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on August 28, 2025.
What other items are reported in this 8-K filing besides the material definitive agreement?
The filing also reports on unregistered sales of equity securities, departure of directors or certain officers, election of directors, appointment of certain officers, and financial statements and exhibits.
What is Akari Therapeutics Plc's SIC code?
Akari Therapeutics Plc's Standard Industrial Classification (SIC) code is 2834, Pharmaceutical Preparations.
What were Akari Therapeutics Plc's former company names?
Akari Therapeutics Plc's former company names were Celsus Therapeutics Plc. (name changed June 21, 2013) and Morria Biopharmaceuticals PLC (name changed February 1, 2012).
Filing Stats: 1,725 words · 7 min read · ~6 pages · Grade level 15.3 · Accepted 2025-08-29 17:01:01
Key Financial Figures
- $0.0001 — tal Market Ordinary Shares, par value $0.0001 per share* *Trading, but only in conn
- $25,000,000 — ated to purchase, up to an aggregate of $25,000,000 (the "Commitment Amount") of newly issu
- $12,500,000 — two-day valuation period for the first $12,500,000 of closings, and 98% thereafter. In n
- $15,000 — will pay a document preparation fee of $15,000, to be deducted from the proceeds relat
- $37,500 — ase Notice, and cash commitment fees of $37,500 when aggregate Purchase Notices exceed
- $500,000 — when aggregate Purchase Notices exceed $500,000 and $87,500 (or $125,000 if $1,000,000
- $87,500 — te Purchase Notices exceed $500,000 and $87,500 (or $125,000 if $1,000,000 is reached f
- $125,000 — Notices exceed $500,000 and $87,500 (or $125,000 if $1,000,000 is reached first) when ag
- $1,000,000 — ed $500,000 and $87,500 (or $125,000 if $1,000,000 is reached first) when aggregate Purcha
- $625,000 — if the Company fails to close at least $625,000 in purchases by the 180th day after the
- $75,000 — ill issue Ordinary Shares equivalent to $75,000 divided by the lowest traded ADS price
Filing Documents
- form8-k.htm (8-K) — 58KB
- ex10-1.htm (EX-10.1) — 281KB
- ex10-2.htm (EX-10.2) — 133KB
- 0001641172-25-026032.txt ( ) — 754KB
- aktx-20250828.xsd (EX-101.SCH) — 4KB
- aktx-20250828_def.xml (EX-101.DEF) — 26KB
- aktx-20250828_lab.xml (EX-101.LAB) — 36KB
- aktx-20250828_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 5KB
02 Departure of Directors or
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 28, 2025, Torsten Hombeck, Chief Financial Officer of the Company, notified the Company of his decision to resign to be effective October 10, 2025. Mr. Hombeck committed thereafter to remain with the Company as a consultant through at least November 30, 2025 to assure a smooth transition of his responsibilities. Mr. Hombeck has advised the Company that his resignation was due to personal reasons and it is not as a result of any disagreement with the Company on any matter related to the operations, policies, or practices of the Company. The Company has initiated a search for a qualified candidate for the CFO position. Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Document 10.1 Ordinary Share Purchase Agreement, dated August 29, 2025, by and between Akari Therapeutics, Plc and White Lion Capital, LLC. 10.2 Registration Rights Agreement, dated August 29, 2025, by and between Akari Therapeutics, Plc and White Lion Capital, LLC 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 3 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Akari Therapeutics, Plc By: /s/ Abizer Gaslightwala Name: Abizer Gaslightwala Title: Chief Executive Officer Dated: August 29, 2025 4